Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
Diagnosis of AIDS and persistent Mycobacterium avium- intracellulare (MAI) bacillemia.
Life expectancy of at least 3 months.
Baseline chest X-ray and EKG (electrocardiogram).
You may not be if
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Known hypersensitivity to interferons or other exogenous lymphokine.
History of cardiac abnormality or disease.
History of hypertension.
Patients with the following are excluded:
Known hypersensitivity to interferons or other exogenous lymphokine.
History of cardiac abnormality or disease.
History of hypertension.
Prior Medication:
Excluded within 4 weeks of study entry:
Corticosteroids.
Anti-inflammatory medication (except aspirin).
Changes in the dose of anti-mycobacterial drugs.
Immune agents.
Prior Treatment:
Excluded within 4 weeks of study entry:
Radiotherapy.
Risk Behavior:
Excluded:
Intravenous drug abuse.
Clareo Health | Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study
